The event demonstrates how regulatory innovation and the use of AI are modernising the drug evaluation process, and provides a concise overview of this for consultancy firms and regulatory affairs departments in the pharmaceutical industry.
Contents
- Approaches outlined in the AI Reflection Paper
- In silico methods in preclinical and PK/PD
- Overview of the use of AI in the regulatory environment at EU level
You can find the detailed programme here.
Target audience
- Consultancy firms in the pharmaceutical industry
- Regulatory affairs departments in the pharmaceutical industry
Language
German
Registration information
Please register by 6 May 2026 at the latest.
This event will be held entirely online.
Technical leadership
Dr Christoph Mück, Dr Georg Neuwirther, Dr Martin Walter, Tobias Fellinger, MSc. Medical
Market Surveillance Division, AGES GmbH
Dr Gerhard Beck
Institute for Regulatory Affairs & Life Cycle Management Medical
Market Surveillance Division, AGES GmbH